PAX3 and melanoma: Co-localization of Ki67 with PAX3 was also relatively infrequent in melanomas including superficial spreading, lentigo maligna melanoma and nodular melanoma, and MMs, with an average of only ∼20% of cells co-expressing Ki67 and PAX3 in the latter (Figure 3).